Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRadimed Corporation (IRMD) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents provide structured detail on financial performance, governance, and material events related to iRadimed’s business of MRI-compatible medical devices, including non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems.
Among the key filings are Form 8-K current reports, which iRadimed uses to announce events such as quarterly financial results, changes in its Board of Directors, and outcomes of stockholder meetings. For example, Form 8-K filings have reported record quarterly revenue, the use of non-GAAP financial measures like non-GAAP net income and free cash flow, the completion of a new facility in Orlando, Florida, and the retirement and appointment of directors. Other 8-Ks furnish press releases that detail FDA 510(k) clearance for the MRidium 3870 IV Infusion Pump System and summarize voting results from the Annual Meeting of Stockholders.
Filings also disclose listing information for iRadimed’s common stock, including its trading symbol IRMD and its listing on the NASDAQ Global Market, with one filing referencing the NASDAQ Capital Market. Governance-related sections describe board committee assignments, independence determinations, and advisory votes on executive compensation. These documents collectively give insight into how the company is overseen and how major decisions are communicated to investors.
On Stock Titan, iRadimed’s SEC filings are paired with AI-powered summaries that explain the contents of lengthy documents in plain language. Users can quickly see the main points of quarterly earnings announcements, board changes, and stockholder votes without reading every page. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while AI-generated highlights help readers identify sections related to financial condition, risk factors, and corporate actions. For those researching IRMD’s regulatory history and ongoing obligations, this page offers a focused view of its official SEC reporting.
IRADIMED CORP director Monty K. Allen reported an open-market sale of company stock. On 02/13/2026, he sold 1,000 shares of common stock in multiple trades at a weighted average price of $100.2563 per share. After this transaction, he directly owned 21,000 shares of IRADIMED CORP common stock.
A shareholder of Iradimed has filed a notice to sell 1,000 shares of common stock under Rule 144 through Raymond James on or around 02/13/2026, to be traded on NASDAQ. The filing lists an aggregate market value of 100,256.26 for the planned sale.
The 1,000 shares come from restricted stock units that vested on 12/07/2025 (95 shares) and 12/11/2025 (905 shares) as compensation for board service. The issuer had 12,722,377 shares outstanding when this notice was prepared.
Nine Ten Capital Management LLC and related reporting persons report beneficial ownership of iRadimed Corp common stock on a Schedule 13G/A Amendment No. 6. They disclose holding 428,477 shares, representing 3.4% of the common stock, as of December 31, 2025.
The filers report sole voting and sole dispositive power over these 428,477 shares. They certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iRadimed Corp.
IRADIMED CORPORATION reported record fourth quarter and full-year 2025 results, with revenue of $22.7 million in Q4, up 17%, and full-year revenue of $83.8 million, up 14% from 2024.
Q4 2025 net income rose to $6.4 million, or $0.50 per diluted share, a 25% year-over-year increase, while non-GAAP diluted EPS reached $0.54. For 2025, net income was $22.5 million, or $1.75 per diluted share, with non-GAAP diluted EPS of $1.93.
The board raised the regular quarterly cash dividend to $0.20 per share from $0.17, payable on March 6, 2026 to shareholders of record on February 23, 2026. Management guided 2026 revenue to $91.0–$96.0 million, GAAP diluted EPS of $1.90–$2.05, and non-GAAP diluted EPS of $2.06–$2.21, reflecting expectations for contributions from the next-generation 3870 MRI-compatible IV infusion pump.
IRADIMED CORP insider activity centers on trust-managed share sales linked to CEO Roger E. Susi. On January 26, 2026, the Phillip Susi 2008 Dynasty Trust sold 4,339 common shares at a weighted average price of $100.54 and 661 shares at $101.38, both under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025.
After these sales, that trust held 2,262,500 shares. The filing also lists 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with Susi expressly disclaiming beneficial ownership of the latter beyond his pecuniary interest.
IRADIMED CORP insider activity: A trust associated with CEO, President and Chairman Roger E. Susi reported three planned sales of common stock on January 20, 2026 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The Phillip Susi 2008 Dynasty Trust sold 2,129 shares at a weighted average price of $101.03, 1,074 shares at $102.03, and 1,797 shares at $102.70. After these transactions, that trust held 2,267,500 shares of IRADIMED common stock. The filing also shows indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with the reporting person disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED Corp insider trusts reported planned stock sales. Trusts associated with CEO, President and Chairman Roger E. Susi sold a total of 5,000 shares of IRADIMED common stock on January 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
The Phillip Susi 2008 Dynasty Trust sold 4,888 shares at a weighted average price of $97.43 and 112 shares at $98.15, leaving it with 2,272,500 shares indirectly reported. Additional indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.
IRADIMED Corporation insider activity centered on trust-held shares linked to its CEO. A trust associated with CEO, President and Chairman Roger E. Susi, the Phillip Susi 2008 Dynasty Trust, sold a total of 5,000 shares of IRADIMED common stock on January 5, 2026 in multiple transactions coded as open-market sales.
The reported weighted average sale prices ranged from $95.10 to $99.48, with underlying trade price ranges disclosed between $94.55 and $99.60, all under a Rule 10b5-1 trading plan adopted on June 16, 2025. After these sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 shares, while additional indirect holdings reported for Roger E. Susi were 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.
Iradimed Corp’s CEO, president, chairman and 10% owner Roger E. Susi reported insider sales of the company’s common stock. On 12/15/2025, a Rule 10b5-1 trading plan arranged for the sale of 4,269 shares at a weighted average price of $96.68 and 731 shares at a weighted average price of $97.13, both through the Phillip Susi 2008 Dynasty Trust.
After these transactions, the form reports indirect beneficial ownership of 2,292,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust. The filing notes the trades were executed under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025, and that beneficial ownership of certain securities is disclaimed except to the extent of pecuniary interest.
Iradimed Corporation director Hilda Scharen-Guivel reported receiving 1,026 restricted stock units on December 11, 2025 under the company’s 2023 Equity Incentive Plan. The units were granted at a price of $0 and each restricted stock unit converts into one share of common stock.
The restricted stock units vest in two equal annual installments beginning on December 11, 2026, spreading the award over two years. After this grant, she beneficially owns 1,932 derivative securities, held directly.